In patients with first recurrence of breast cancer high plasma YKL-40 predicted less responsiveness to anthracycline therapy [48], and high plasma YKL-40 was a predictor of second-line chemo resistance in patients with ovarian cancer [64]. The gene discussed is CHI3L1; the disease is ovarian carcinoma.